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Abstract: Saliva is an easy accessible plasma ultra-ﬁ  ltrate. Therefore, saliva can be an attractive alternative to blood for 
measurement of diagnostic protein markers. Our aim was to determine stability and protein composition of saliva. Protein 
stability at room temperature was examined by incubating fresh whole saliva with and without inhibitors of proteases 
and bacterial metabolism followed by Surface Enhanced Laser Desorption/Ionization (SELDI) analyses. Protein com-
position was determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) fractionation of 
saliva proteins followed by digestion of excised bands and identiﬁ  cation by liquid chromatography tandem mass spec-
trometry (LC-MS/MS). Results show that rapid protein degradation occurs within 30 minutes after sample collection. 
Degradation starts already during collection. Protease inhibitors partly prevented degradation while inhibition of bacte-
rial metabolism did not affect degradation. Three stable degradation products of 2937 Da, 3370 Da and 4132 Da were 
discovered which can be used as markers to monitor sample quality. Saliva proteome analyses revealed 218 proteins of 
which 84 can also be found in blood plasma. Based on a comparison with seven other proteomics studies on whole saliva 
we identiﬁ  ed 83 new saliva proteins. We conclude that saliva is a promising diagnostic ﬂ  uid when precautions are taken 
towards protein breakdown.
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Introduction
Saliva is a plasma ultra-ﬁ  ltrate that includes speciﬁ  c salivary proteins produced by three major salivary 
glands (parotid, sub-mandibular and sub-lingual) and other smaller glands (Baum, 1993). Salivary 
glands produce around 750 ml of ﬂ  uid each day (Chicharro, 1998). After secretion in the mouth cavity, 
the ﬂ  uid is mixed with bacteria, lining cells, nasal secretions and bronchial secretions and is termed 
whole saliva (Kaufman, 2000; Kaufman, 2002). Whole saliva is easy to collect in a non-invasive way. 
This makes saliva an attractive alternative to blood testing (Kaufman, 2002; Lawrence, 2002). Compared 
to blood sampling, whole saliva collection requires no specially trained personnel, can reduce discom-
fort and anxiety and may simplify serial sample collection. Saliva tests are also safer than blood tests 
regarding the risk for hepatitis and HIV. As a diagnostic ﬂ  uid, saliva has been studied in pilot experi-
ments for several pathological conditions, such as celiac disease (Lanander-Lumikari, 2000), rheuma-
toid arthritis (Helenius, 2005), HIV (Holmstrom, 1990; Malamud, 1992; Matsuda, 1993; Frerichs, 1994), 
diabetes mellitus (Belazi, 1998; Lopez, 2003), preterm birth (Heine, 2000; Ramsey, 2003), breast can-
cer (Streckfus, 2005; Streckfus, 2006), sjögren’s syndrome (Ryu, 2006) and for evaluation of hemato-
poietic stem cell transplantation (Imanguli, 2007). Saliva composition is inﬂ  uenced by several factors, 
e.g. circadian rhythms, oral health status and exercise (Dawes, 1993; Chicharro, 1998) but also micro 
organisms and proteases may have a considerable effect on sample stability/protein degradation. Before 
saliva can be used as a diagnostic ﬂ  uid for protein markers in the clinic, its stability should be deter-
mined. At present there are only three studies on protein stability in saliva samples (Morris, 2002; Ng, 
2003; Schipper, 2007). Two of the studies report on the stability of speciﬁ  c proteins i.e. IgA, Lysozyme 
(Ng, 2003) and IgG (Morris, 2002). One recent study determined overall protein stability of saliva 
samples stored on ice, at −20 °C and at −80 °C (Schipper, 2007). In the current study we evaluated in 
detail the overall protein stability of saliva at room temperature over the ﬁ  rst four hours after sample 26
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collection since this is a critical period where 
protein breakdown could be expected. The effect 
of sample handling, inhibition of bacterial growth 
and inhibition of protease activity on saliva protein 
stability was examined by comparative proﬁ  ling 
with Surface Enhanced Laser Desorption/Ioniza-
tion Time of Flight Mass Spectrometry (SELDI-
TOF-MS) (Merchant, 2000). In addition we 
studied whole saliva composition. Whole saliva 
protein composition has been studied using differ-
ent proteomic strategies (Huang, 2004; Vitorino, 
2004; Wilmarth, 2004; Hu, 2005; Xie, 2005; Guo, 
2006; Walz, 2006). Xie et al. (Xie, 2005) identiﬁ  ed 
437 proteins in saliva using free ﬂ  ow electropho-
reses. Guo et al. (Guo, 2006) could identify 1381 
proteins employing a capillary electrophoresis 
approach. However, because of the complexity of 
whole saliva, each proteomics strategy leads to 
partial overlapping subsets of saliva proteins (Guo, 
2006). Therefore, different proteomics strategies 
contribute to a comprehensive view of the whole 
saliva proteome. We analyzed whole saliva com-
position by fractionating saliva proteins on SDS-
PAGE followed by LC- MS/MS analyses of digests 
from cut-out sections of the gel lane. This pro-
teomics approach has not been applied to saliva 
before. The results of this approach are compared 
to previous proteomics studies on whole saliva and 
discussed in terms of protein origin and function.
Materials and Methods
Chemicals
Ammonium bicarbonate, triton X-100, azide, 
phenylmethylsulphonylﬂ  uoride (PMSF), EDTA, 
ditiothreitol (DTT), iodoacetamide, α-cyano-4-
hydroxy cinnamic acid diethylamine salt (CHCA), 
formic acid (FA) and triﬂ  uoroacetic acid (TFA) 
were purchased from Sigma-Aldrich (Steinheim, 
Germany). Acetonitrile (ACN) and acetone were 
obtained from Biosolve (Valkenswaard, The 
Netherlands), leupeptin from Roche (Mannheim, 
Germany) and ammonium acetate and 2-propanol 
from Merck (Darmstadt, Germany). MES running 
buffer and SeeBlue Pre-Stained standard for SDS-
PAGE were obtained from Invitrogen (Breda, The 
Netherlands). Coomassie staining (PageBlue 
Staining Solution) was from Fermentas (Vilnius, 
Lithuania). Seq. grade modiﬁ  ed trypsin porcine 
was purchased from Promega (Madison, WI, 
U.S.A.).
Saliva collection
Whole saliva was collected from healthy subjects, 
four male and three female, between 08:00 a.m. 
and 10:00 a.m. after overnight fasting, to minimize 
the inﬂ  uence of circadian rhythms and food debris. 
Subjects were asked to rinse their mouths with 
water and discard this before sample collection. 
Saliva was allowed to accumulate in the ﬂ  oor of 
the mouth. The accumulated saliva was then spit 
into a polypropylene test tube and this was repeated 
until enough saliva was collected (Navazesh, 
1993). During the collection process the sample 
tubes were kept on ice.
Sample pretreatment
Samples were processed according to Hu et al. (Hu, 
2005). Brieﬂ  y, samples were centrifuged for 5 
minutes at 1300 g at 4 °C. The pellet was discarded 
(debris) and the supernatant was centrifuged for 
15 minutes at 14000 g at 4 °C. After centrifugation, 
the supernatant was stored at −20 °C until analysis. 
Samples were analyzed the same day.
Sample stability studies
In the ﬁ  rst experiment, sample stability was deter-
mined in saliva obtained from seven healthy vol-
unteers (four male, three female). Freshly collected 
saliva samples were either directly processed (time 
point 0) or left at room temperature for four hrs 
before processing. Aliquots of the 0 and 4 hrs time 
points were then analyzed by SELDI-TOF-MS in 
duplicate (see below).
In a second experiment a unique saliva sample 
freshly collected from one healthy male volunteer 
was divided in 3 aliquots of 1.2 ml and incubated 
for 0, 0.5, 1 and 4 hrs at room temperature with 
either a) 40 μl of 100 mM sodium azide to inhibit 
bacterial activity, b) protease inhibitors: 60 μl of 2 
mg/ml PMSF in 2-propanol, 1.2 μl of 1 mg/ml 
leupeptin in water, 12 μl of 100 mM EDTA, or c) 
no additives (control). Water was added to a ﬁ  nal 
volume of 1.273 ml for all 3 conditions. At each 
time point an aliquot was taken and treated as 
described above (sample pre-treatment section). 
Thereafter, samples were analyzed in triplicate by 
SELDI-TOF-MS for protein proﬁ  ling.
CM10 weak cation exchange proteinchip arrays 
(Ciphergen biosystems, Fremont, CA, U.S.A.) were 
assembled in a 96 well bioprocessor and the spots 
were washed two times with 200 μl binding buffer 27
Stability and composition of the saliva proteome
Biomarker Insights 2008:3 
(100 mM NH4Ac pH 4.0, 0.05% Triton X-100) for 
5 minutes with vigorous shaking. After removing 
the buffer from the wells, 90 μl binding buffer and 
10 μl saliva sample were randomly applied to the 
spots (in duplicate or triplicate as detailed above). 
Samples were allowed to incubate for 30 minutes 
with continuous shaking. Then, they were removed 
and spots were washed 3 times with 200 μl binding 
buffer for 5 minutes and once with 200 μl de-ionized 
water for 5 minutes. The chips were removed from 
the bioprocessor and air-dried for 15 minutes, 
followed by two additions (1 μl each) of a 20% 
solution of CHCA prepared in 50% ACN and 0.5% 
TFA. Spots were analyzed using the ProteinChip 
Reader (model PBS II, Ciphergen Biosystems). The 
mass spectrometer was calibrated using the All-in-
One peptide calibration kit (Ciphergen Biosystems) 
with a focus mass of 6000 Da. Spectra from the 
saliva samples were collected with the proteinchip 
software 3.1 (Ciphergen Biosystems) in the mass 
range 1–20 kDa. Laser intensity was 190, ionsource 
voltage 20000 V and detector voltage 2150 V. 
Cluster analysis was performed by Ciphergen 
Express 3.0 software (Ciphergen Biosystems): a) 
between samples collected at 0 hr and 4 hr, 
combining spectra of all seven volunteers measured 
in duplicate (28 spectra in total) and b) between 
different time points (0 hrs, 0.5 hrs, 1 hr and 4 hrs) 
for every condition (control, in presence of azide 
and in presence of protease inhibitors) measured in 
triplicate. Before cluster analyses, spectra to be 
compared were selected, the baseline was subtracted 
and proﬁ  les were normalized using total ion current. 
Peaks with a signal to noise ratio higher than 5 were 
selected and were clustered with peaks with similar 
masses (mass deviation 0.3%) in other proﬁ  les with 
signal to noise ratios higher than 2. The percentage 
of spectra in which a peak must appear in order to 
form a cluster was set to 20%. Signiﬁ  cant differences 
(p   0.05) in peak height of particular masses were 
calculated.
Saliva protein composition
A saliva sample freshly obtained from a healthy 
volunteer was processed immediately after collec-
tion as described in the sample pretreatment sec-
tion. 10 μl of processed saliva were mixed with 
NuPAGE LDS sample buffer (Invitrogen, Carls-
bad, CA, U.S.A.) according to standard protocol 
from the manufacturer. SDS-PAGE was then per-
formed on a NuPAGE 12% Bis-Tris gel (Invitrogen) 
run at 200 V for 50 minutes with MES buffer 
(Invitrogen). Proteins were visualized with Coo-
massie staining. For protein identiﬁ  cation, the 
whole lane was excised in 30 bands. Each band 
was cut into small pieces and stored at −20 °C until 
analysis. Then, they were washed in water and 
dehydrated in ACN. Reduction was performed by 
covering gel pieces with 10 mM DTT in 100 mM 
ammonium bicarbonate for 1 hr at 60 °C. DTT 
solution was then replaced by 55 mM iodoacet-
amide in 100 mM ammonium bicarbonate and gel 
pieces were incubated at room temperature in the 
dark for 45 minutes. After washing in water and 
dehydration in ACN, 0.1 μg of trypsin (in 50 mM 
ammonium bicarbonate) was added and gel pieces 
were allowed to rehydrate on ice for 20 minutes. 
Digestion was carried out overnight at 37 °C. Pep-
tides were extracted by treating the gel pieces with 
0.1%FA for 30 minutes with continuous shaking. 
Peptide mixtures were then stored at −20 °C until 
LC-MS/MS analysis was performed.
Separation of the resulting tryptic peptide mix-
tures was performed by nano-scale reversed-phase 
LC-MS/MS. The Agilent 1100 nanoﬂ  ow/capillary 
LC system (Agilent, Paolo Alto, CA, U.S.A.) was 
equipped with a trapping column (5 × 0.3 mm 
C18RP) (Dionex/LC Packings, Amsterdam, The 
Netherlands) and a nanocolumn (150 × 0.075 mm, 
C18Pepmap) (Dionex/LC Packings). Peptides mix-
tures were injected into the trapping column at a 
ﬂ  ow rate of 10 μl/min (3%ACN/0.1%TFA). After 
10 minutes the trapping column was switched into 
the nanoﬂ  ow system and the trapped peptides were 
separated using the nanocolumn at a ﬂ  ow rate of 
0.3 μl/min in a linear gradient elution from 95%A 
(3%ACN/0.1%TFA) to 50%B (97%ACN/
0.1%TFA) in 70 minutes, followed by an increase 
up to 80%B in 5 minutes. The eluting peptides 
were on-line electrosprayed into the QStar XL 
Hybrid ESI Quadrupole time-of-flight tandem 
mass spectrometer, ESI-QTOF-MS/MS (Applied 
Biosystems, Framingham, MA; MDS Sciex, Con-
cord, Ontario, Canada) provided with a nanospray 
source equipped with a New Objective ESI needle 
(10 μm tip diameter). Typical values for needle 
voltage were 2 kV in positive ion mode. The mass 
spectrometer was set to perform data acquisition 
in the positive ion mode, typically with a selected 
mass range of 300–1500 m/z. Peptides with +2 to 
+4 charge states were selected for tandem mass 
spectrometry, and the time of summation of MS/
MS events was set to be 2 s. The three most 28
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abundant charged peptides above a 30 count thresh-
old were selected for MS/MS and dynamically 
excluded for 60 s with 50 amu mass tolerance.
ProID software (Applied Biosystems) was used 
to identify proteins from the mass spectrometric 
datasets according to UniProt database (May 2005, 
181,000 entries). Mass tolerance was set to 0.15 
Da (MS) and 0.1 Da (MS/MS) and carboxamido-
methylation and methionine oxidation were chosen 
as modiﬁ  cations for database search.
Results
Sample stability
The stability of saliva at room temperature after 
sample collection from four male and three female 
volunteers was evaluated. Freshly collected saliva 
samples were either directly processed (time point 0) 
or left at room temperature for 4 hrs and processed 
as described in the sample pretreatment section. 
Aliquots taken at the two time points were then 
spotted in duplicate on CM10 weak cation 
exchange chips and protein proﬁ  les were obtained 
by SELDI-TOF-MS. Representative spectra 
obtained from the 1 to 10 kDa range are shown 
in Figure 1. In this mass range degradation prod-
ucts of larger proteins can be expected. When 
comparing the protein proﬁ  les of fresh samples 
(0 hrs) of the seven volunteers (A-G) it is evident 
that there is already considerable variation, espe-
cially in the mass range of 1 to 5 kDa between 
the different individuals. This may be due to 
biological variation and/or may indicate different 
degrees of protein degradation between individu-
als. Also over the period of 4 hrs at room tem-
perature many changes in the spectra can be 
observed (Fig. 1). To ﬁ  nd common peaks that were 
changed over the 4 hrs period in all seven samples 
we performed a cluster analyses on the acquired 
spectra. In total 11 differences were detected and 
listed in Table 1 together with their fold change 
in peak intensity between the two conditions. 
Most peptides are decreased in abundance at 4 hrs, 
probably because they are further degraded into 
single amino acids during this period. However, 
3 peptides with masses 2937 Da, 3370 Da and 
4132 Da are increasing in time which indicates 
that they are relatively stable breakdown products 
of larger proteins. Although SELDI technology 
allows rapid comparison of sample composition, 
protein/peptide identification is troublesome 
because it involves puriﬁ  cation of each degrada-
tion product. Therefore, we attempted to identify 
the 2937 Da breakdown product by direct SELDI-
MS/MS which is possible for peptides with 
masses below 3000 Da. However, the 2937 Da 
peptide could not be fragmented by MS/MS even 
with the highest energy settings and argon as col-
lision gas. This indicates that it is very stable, 
possibly due to a high degree of post-translational 
modiﬁ  cations such as glycosylation which may 
also explain its stability in vivo. As Figure 2 
indicates, the three marker peptides can already 
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Figure 1. Sample stability at room temperature. Protein proﬁ  les of saliva 
samples of seven volunteers (A-G) taken at 0 and 4 hrs of incubation 
at room temperature are shown for the mass range of 1000 to 10000 
Da. Protein proﬁ  les were generated using CM10 proteinchips and 100 
mM NH4Ac pH 4.0 as binding and washing buffer. CHCA was used as 
matrix.29
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be detected in “fresh” samples (0 hrs), although 
with lower intensities. This indicates that 
breakdown already starts during sample collection 
and suggests that these markers may be useful 
indicators of protein breakdown in saliva samples. 
We examined the protein degradation in saliva in 
detail to obtain more knowledge on the time frame 
of the degradation process and whether it was 
possible to inhibit degradation. Protein degrada-
tion could be caused by bacteria in the mouth 
cavity and/or by proteases present in saliva. 
Therefore, we studied the inﬂ  uence of sodium 
azide, an inhibitor of bacterial energy metabolism, 
and of a protease inhibitor cocktail consisting of 
PMSF, leupeptin (both serine and cysteine 
protease inhibitors) and EDTA, an inhibitor of 
metallo-proteases. Saliva samples were incubated 
for 0, 0.5, 1 and 4 hrs in the presence and absence 
of the above mentioned inhibitors. Subsequently, 
protein proﬁ  les were generated (Fig. 3) and com-
pared for differences by cluster analyses as 
described above. In Figure 4 the number of sig-
niﬁ  cant differences is depicted for the different 
conditions and the different time points compared 
to 0 hrs (control). For saliva without inhibitors 
already 19 differences were observed in the ﬁ  rst 
30 minutes incubation. Thereafter, the number of 
differences stabilizes. This can be explained by 
assuming that equilibrium has been reached at 
this point between the formation of peptides from 
the breakdown of larger proteins and the 
degradation of these peptides into single amino 
acids which are in the mass range of the matrix 
peaks and therefore are not detected. At 4 hrs 
26 differences were observed compared to 0 hrs. 
This indicates that protein degradation in saliva 
is a relatively rapid process. It is also clear from 
Figure 4 that protein breakdown is almost not 
affected by the addition of azide to the samples, 
indicating that bacterial metabolism is not con-
tributing much to the protein degradation process, 
at least for the ﬁ  rst hour after collection. The 
protease inhibitor cocktail is more effective in 
slowing down the degradation process (Fig. 4). 
At 4 hrs, 19 differences were observed in the 
presence of protease inhibitors compared to 26 
differences in the control sample. Nevertheless, 
protein degradation is still substantial with the 
inhibitor cocktail used. Different inhibitors or 
combinations of inhibitors need to be evaluated 
to determine their effectiveness.
The saliva proteome
To determine the saliva composition, saliva 
proteins were fractionated by SDS-PAGE (Fig. 5). 
The whole lane was sliced into 30 bands and 
digested by trypsin. The digests of the bands were 
subjected to LC-MS/MS for protein identiﬁ  cation, 
as described in detail in the Materials and Methods 
section. In total we identiﬁ  ed 218 proteins, 182 
with 99% conﬁ  dence and 36 with 95% conﬁ  dence. 
A complete list of identiﬁ  ed proteins is shown in 
Table 2. Proteins were classiﬁ  ed into 12 functional 
categories based on information from Swiss Prot, 
Source and Human Protein Reference Database. 
Table 1. Masses with signiﬁ  cantly different peak inten-
sities between 0 and 4 hrs of incubation of whole saliva 
at room temperature.
Peak (m/z)  p-value  Fold change
2937 0.0017 6.8
3370 0.025  2.0
4132 0.047  3.0
4368 0.0017  −6.1
4928 0.0017  −17.5
5210 0.018 −3.7
5376 0.0017  −16.5
5839 0.018 −2.8
7751 0.0017  −6.1
10422 0.0088 −5.0
15495 0.0017 −4.9
Clusters were determined using S/N   5 (ﬁ  rst pass) and S/N   2 
(second pass). Differences were considered signiﬁ  cant if p   0.05.
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Figure 2. Detailed view of the SELDI proﬁ  le of volunteer A (see also 
Fig. 1) in the mass range of 2500 to 5000 Da for saliva samples taken 
at 0 and 4 hrs of incubation at room temperature. The labeled peaks 
are discovered degradation markers. The complete list of markers 
is shown in Table 1.30
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For each protein also the functional category is 
listed. In Figure 6 an overview of the different 
categories is given. The largest category (19.2%) 
consists of enzymes involved in metabolism, 
mainly in carbohydrate metabolism (12.8%). This 
includes enzymes such as α-amylase, lactate dehy-
drogenase, malate dehydrogenase and fructose-
biphosphate aldolase. Another important category 
(17.9%) includes proteins that are involved in 
immune response and defense against bacteria. In 
this group there is a large cluster of IgG chains 
besides antibactericidal peptides such as dermcidin 
and bactericidal permeability-increasing protein. 
Also many proteins from bacterial origin were 
identiﬁ  ed (11% of total). 10.6% of the proteins are 
involved in degradation. Six proteases were iden-
tiﬁ  ed in this group e.g. kallikrein, cathepsin D and 
lysozyme C. Thirteen protease inhibitors are also 
part of this category such as cystatins, alpha-2-
macroglobulin and TIMP-1. The proteases are 
likely to contribute to the rapid breakdown of saliva 
proteins that was described above. Also many 
structural proteins (14.7% of total) were found 
which are probably derived from cells lining the 
mouth cavity together with other intracellular 
proteins that were identiﬁ  ed. The transport proteins 
(8.3% of total) are mainly serum-derived such as 
albumin, apolipoprotein A-1, transferrin, and ceru-
loplasmin. Minor categories of proteins are 
signaling (5.5%), protein modiﬁ  cation (4.6%), cell 
growth and differentiation (2.3%), cell adhesion 
(3.7%), and proteins involved in maintaining redox 
status (2.3%). We also compared our results, listed 
in Table 2, to the HUPO plasma proteome initiative 
list of 3020 plasma proteins, identiﬁ  ed with at least 
two peptides by LC-MS/MS (www.bioinformatics.
med.umich.edu/hupo/ppp). According to the 
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Figure 3. Representative SELDI spectra of a saliva sample incubated 
at 0, 0.5, 1 and 4 hrs at room temperature in the absence (control) 
and presence of sodium azide, an inhibitor of bacterial metabolism, 
and a protease inhibitor cocktail.
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Figure 4. Number of signiﬁ  cant differences in peak intensity between 
the different conditions (● control, + azide and ▲protease inhibitors) 
and the different time points compared to 0 hrs. Differences were 
calculated from the spectra (Fig. 3) for the mass ranges of 1000 to 20000 
Da using cluster analyses of triplicate measurements of the samples. 
Clusters were deﬁ  ned using S/N   5 (ﬁ  rst pass) and S/N   2 (second 
pass). Differences were considered signiﬁ  cant if p   0.05.31
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Table 2. List of proteins identiﬁ  ed with 99% and 95% conﬁ  dence in human saliva.
Protein name  Accession nr  Function  Mass (Da)
99% conﬁ  dence:     
14-3-3 protein beta/alpha  P31946  Signalling  27951
14-3-3 protein zeta/delta
§ P63104  Signalling  27745
6-phosphogluconate dehydrogenase,  P52209  Energy/metabolism  53009
decarboxylating
78 kDa glucose-regulated protein  P11021  Protein Folding/Repair  72333
precursor
§
Actin
§ P60709  Structural/Cytoskeletal  41737
Actin-like protein 3
# P61158  Structural/Cytoskeletal  47240
Actin-related protein 2/3 complex  P59998  Structural/Cytoskeletal  19536
subunit 4
#
Adenine phosphoribosyltransferase  P07741  Energy/metabolism  19477
Adenosylhomocysteinase
# P23526  Energy/metabolism  47585
Alcohol dehydrogenase [NADP+]
# P14550  Energy/metabolism  36442
Alcohol dehydrogenase class IV  P40394  Energy/metabolism  40006
mu/sigma chain
#
Aldehyde dehydrogenase, dimeric  P30838  Energy/metabolism  50379
NADP-preferring
#
Aldo-keto reductase family  O60218  Energy/metabolism  36021
1 member B10
Alpha enolase
§ P06733  Energy/metabolism  47038
Alpha-1-acid glycoprotein 1  P02763  Defense/Immunoresponse  23512
precursor
§,#
Alpha-1-antitrypsin precursor
§ P01009  Protein  Degradation/Inhibitor  46737
Alpha-actinin 1
§ P12814  Structural/Cytoskeletal  103058
Apolipoprotein A-I precursor
§ P02647  Transport  30778
Arginase 1
§ P05089  Energy/metabolism  34735
ATPase 4, plasma membrane-type
# Q9SU58  Micro  organism  105718
Bactericidal permeability-increasing  P17213  Transport  53396
protein precursor
#
Calgranulin B
§ P06702  Cell  Adhesion/Communication  13242
Carbonic anhydrase VI precursor
§ P23280  Energy/metabolism  35365
Carboxylesterase 2 precursor  O00748  Energy/metabolism  61807
Cathepsin D precursor  P07339  Protein Degradation/Inhibitor  44552
Ceruloplasmin precursor
§ P00450  Transport  122205
Chaperone protein dnaK
# Q7NXI3  Micro  organism  69122
Chitinase 3-like protein 2 precursor
# Q15782  Cell  Growth/Differentiation  43501
Chloride intracellular channel protein 1  O00299  Transport  26792
Clusterin precursor
§ P10909  Cell  Growth/Differentiation  52495
Coﬁ  lin, non-muscle isoform  P23528  Structural/Cytoskeletal  18371
Complement C3 precursor
§ P01024  Signalling  187164
Complement C4 precursor
§ P01028  Defense/Immunoresponse  192771
Complement factor H precursor
§,# P08603  Energy/  metabolism  139070
Coronin-1A P31146  Structural/Cytoskeletal  50895
Cystatin A
§ P01040  Protein  Degradation/Inhibitor  11006
Cystatin B
§ P04080  Protein  Degradation/Inhibitor  11140
Cystatin C precursor
§ P01034  Protein  Degradation/Inhibitor  15799
Cystatin D precursor  P28325  Protein Degradation/Inhibitor  16080
Cystatin S precursor  P01036  Protein Degradation/Inhibitor  16214
Cystatin SA precursor  P09228  Protein Degradation/Inhibitor  16445
Cystatin SN precursor  P01037  Protein Degradation/Inhibitor  16362
Dermcidin precursor
§,# P81605  Defense/Immunoresponse  11284
Desmocollin-2 precursor  Q02487  Cell Adhesion/Communication  99962
Desmoglein-3 precursor  P32926  Cell Adhesion/Communication  107503
Diablo homolog, mitochondrial precursor
# Q9NR28  Signalling  27131
Dihydroxy-acid dehydratase
# Q8XWR1  Micro  organism  58965
Dipeptidyl peptidase IV
§,# P27487  Protein  Degradation/Inhibitor  88279
DNA polymerase IV
# Q9JYS8  Micro  organism  35966
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Table 2. (Continued)
Protein name  Accession nr  Function  Mass (Da)
Elongation factor 1-alpha
§ P68104  Protein  Synthesis  50141
Elongation factor 1-gamma  P26641  Protein Synthesis  49988
Ezrin
§,# P15311  Cell  Growth/Differentiation  69268
F-actin capping protein beta subunit  P47756  Structural/Cytoskeletal  31219
Farnesyl pyrophosphate synthetase
# P14324  Energy/metabolism  40532
Fatty acid-binding protein, epidermal  Q01469  Energy/metabolism  15033
Fibrinogen gamma chain precursor
§ P02679  Protein  Modiﬁ  cation/Polymerization  51512
FixC protein
# Q8Z9K9  Micro  organism  45687
Fructose-bisphosphate aldolase A
§ P04075  Energy/metabolism  39289
Fructose-bisphosphate aldolase C  P09972  Energy/metabolism  39325
Galectin-3 binding protein precursor
§ Q08380  Cell  Adhesion/Communication  65331
Galectin-7
§ P47929  Cell  Adhesion/Communication  14944
Gelsolin precursor
§ P06396  Structural/Cytoskeletal  85698
Genome polyprotein
# P17593  Micro  organism  255497
Glucose-6-phosphate isomerase
§ P06744  Energy/  metabolism  63016
Glutaminyl-tRNA synthetase
# Q8EG26  Micro  organism  64103
Glutathione S-transferase P  P09211  Signalling  23225
Glyceraldehyde-3-phosphate P04406  Energy/metabolism  35922
dehydrogenase 1
Haptoglobin precursor  P00738  Transport  45205
Heat shock 70 kDa protein 1
§ P08107  Protein  Folding/Repair  70052
Heat shock cognate 71 kDa protein
§ P11142  Protein  Folding/Repair  70898
Hemoglobin alpha chain  P69905  Transport  15126
Hemoglobin beta chain  Q9UK54  Transport  13964
Hemopexin precursor
§ P02790  Transport  51676
Hurpin Q9UIV8  Protein  Degradation/Inhibitor  44276
Hypothetical 84.6 kDa protein
# Q04263  Micro  organism  84602
Ig alpha-1 chain C region  P01876  Defense/Immunoresponse  37655
Ig alpha-2 chain C region
§ P01877  Defense/Immunoresponse  36508
Ig gamma-1 chain C region
§ P01857  Defense/Immunoresponse  36106
Ig gamma-2 chain C region
§ P01859  Defense/Immunoresponse  35885
Ig heavy chain V region MOPC 47A
# P01786  Defense/Immunoresponse  12975
Ig heavy chain V-II region NEWM
# P01825  Defense/Immunoresponse  12790
Ig heavy chain V-III region GAL
§,# P01781  Defense/Immunoresponse  12731
Ig heavy chain V-III region HIL
# P01771  Defense/Immunoresponse  13566
Ig heavy chain V-III region TUR
§,# P01779  Defense/Immunoresponse  12431
Ig heavy chain V-III region VH26  P01764  Defense/Immunoresponse  12582
precursor
#
Ig kappa chain C region
# P01834  Defense/Immunoresponse  11609
Ig kappa chain V-I region CAR
§ P01596  Defense/Immunoresponse  11608
Ig kappa chain V-I region WEA
§,# P01610  Defense/Immunoresponse  11704
Ig kappa chain V-I region  P01611  Defense/Immunoresponse  11840
Ig kappa chain V-III region B6
§,# P01619  Defense/Immunoresponse  11636
Ig kappa chain V-III region GOL
§ P04206  Defense/Immunoresponse  11830
Ig kappa chain V-IV region Len
§ P01625  Defense/Immunoresponse  12640
Ig lambda chain C regions
# P01842  Defense/Immunoresponse  11237
Ig lambda chain V-I region NEW
# P01701  Defense/Immunoresponse  11453
Ig lambda chain V-I region WAH
§,# P04208  Defense/Immunoresponse  11725
Ig lambda chain V-III region LOI
§ P80748  Defense/Immunoresponse  11935
Ig lambda chain V-III region SH
§ P01714  Defense/Immunoresponse  11393
Ig lambda chain V-IV region Hil  P01717  Defense/Immunoresponse  11517
Ig mu chain C region  P01871  Defense/Immunoresponse  49557
Immunoglobulin J chain
§ P01591  Defense/Immunoresponse  15594
Interleukin-1 receptor antagonist prec.  P18510  Defense/Immunoresponse  20055
Kallikrein 1 precursor  P06870  Protein Degradation/Inhibitor  28890
Keratin, type I cuticular HA3-II
§,# Q14525  Structural/Cytoskeletal  46214
Keratin, type I cytoskeletal 10  P13645  Structural/Cytoskeletal  59519
Keratin, type I cytoskeletal 14
§,# P02533  Structural/Cytoskeletal  51490
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Table 2. (Continued)
Protein name  Accession nr  Function  Mass (Da)
Keratin, type I cytoskeletal 16
§ P08779  Structural/Cytoskeletal  51137
Keratin, type I cytoskeletal 9
§ P35527  Structural/Cytoskeletal  62129
Keratin, type I microﬁ  brillar 48 kDa
# P02534  Structural/Cytoskeletal  46674
Keratin, type II cuticular HB4
# Q9NSB2  Structural/Cytoskeletal  64895
Keratin, type II cytoskeletal 1
# P04104  Structural/Cytoskeletal  65092
Keratin, type II cytoskeletal 1
§ P04264  Structural/Cytoskeletal  65886
Keratin, type II cytoskeletal 2 epidermal
§ P35908  Structural/Cytoskeletal  65865
Keratin, type II cytoskeletal 4
§ P19013  Structural/Cytoskeletal  57285
Keratin, type II cytoskeletal 5
§ P13647  Structural/Cytoskeletal  62447
Keratin, type II cytoskeletal 6A  P02538  Structural/Cytoskeletal  59914
Keratin, type II cytoskeletal 6D
# P48667  Structural/Cytoskeletal  42468
Keratin, type II cytoskeletal 6E  P48668  Structural/Cytoskeletal  59894
Keratin, type II microﬁ  brillar,  P15241  Structural/Cytoskeletal  53682
component 7C
#
Lactoperoxidase precursor  P22079  Redox  80288
Lactotransferrin precursor
§ P02788  Transport  78182
Leukotriene A-4 hydrolase  P09960  Energy/metabolism  69154
L-lactate dehydrogenase A chain
§ P00338  Energy/metabolism  36558
L-lactate dehydrogenase B chain
§ P07195  Energy/metabolism  36507
Long palate, lung and nasal epith.  Q8TDL5  Defense/Immunoresponse  52442
carc.ass. prot.1prec.
L-plastin
§ P13796  Structural/Cytoskeletal  70158
Lysozyme C precursor  P61626  Protein Degradation/Inhibitor  16537
Macrophage capping protein  P40121  Structural/Cytoskeletal  38518
Malate dehydrogenase, cytoplasmic  P40925  Energy/metabolism  36295
Maspin precursor  P36952  Protein Degradation/Inhibitor  42138
Matrix metalloproteinase-9 precursor
§ P14780  Protein  Degradation/Inhibitor  78427
Maturase K
# Q9GI85  Micro  organism  61017
Metalloproteinase inhibitor 1 prec.
§ P01033  Protein  Degradation/Inhibitor  23171
Moesin P26038  Structural/Cytoskeletal  67689
Monocyte differentiation antigen CD14  P08571  Defense/Immunoresponse  40076
precursor
§,#
Mucin 5B precursor  Q9HC84  Cell Adhesion/Communication  590499
Myeloperoxidase precursor  P05164  Defense/Immunoresponse  83869
Myoglobin
# P02144  Transport  17053
Myosin heavy chain, non-muscle type A
§ P35579  Structural/Cytoskeletal  226401
N-acetylglucosamine kinase
# Q9UJ70  Energy/metabolism  37244
Neutrophil gelatinase-associated  P80188  Transport  22588
lipocalin prec.
§
Outer membrane usher protein pefC  P37868  Micro organism  86370
precursor
#
Peptidyl-prolyl cis-trans isomerase A  P62937  Protein Folding/Repair  17881
Peroxiredoxin 5, mitochondrial precursor  P30044  Redox  22026
Peroxiredoxin 6  P30041  Redox  24904
Phosphatidylethanolamine-binding protein  P30086  Protein Degradation/Inhibitor  20926
Phosphoglucomutase
§,# P36871  Energy/metabolism  61318
Phosphoglycerate kinase 1  P00558  Energy/metabolism  44483
Phosphoglycerate mutase 1  P18669  Energy/metabolism  28673
Phospholipid transfer protein prec.
§,# P55058  Energy/metabolism  54739
Plasminogen activator inhibitor-2 prec.
# P05120  Signalling  46596
Polymeric-immunoglobulin receptor  P01833  Defense/Immunoresponse  83314
precursor
Proactivator polypeptide precursor  P07602  Protein Degradation/Inhibitor  58113
Proﬁ  lin-1
§ P07737  Structural/Cytoskeletal  14923
Prolactin-inducible protein precursor
§ P12273  Defense/Immunoresponse  16572
Proline-rich protein 3 precursor  P02814  Unknown  8188
peptide P-B)
Prominin 1 precursor
# O43490  Signalling 97202
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Table 2. (Continued)
Protein name  Accession nr  Function  Mass (Da)
Protein-glutamine glutamyltransferase  Q08188  Energy/metabolism  76632
E prec.
§
Purine nucleoside phosphorylase  P00491  Energy/metabolism  32118
Pyruvate kinase, isozymes M1/M2
§ P14618  Energy/metabolism  57806
Rab GDP dissociation inhibitor beta  P50395  Signalling  50663
Ras-related C3 botulinum toxin  P15153  Transport  21429
substrate 2
#
Rho GDP-dissociation inhibitor 2  P52566  Signalling  22857
S100 calcium-binding protein A7
§ P31151  Cell  Growth/Differentiation  11326
Salivary alpha-amylase precursor  P04745  Energy/metabolism  57768
Serine/threonine-protein kinase BRI1-  Q9ZPS9  Energy/metabolism  39280
like 2 precursor
#
Serine/threonine-protein kinase RIPK4
# P57078  Energy/metabolism  91611
Serotransferrin precursor
§ P02787  Transport  77050
Short palate, lung and nasal  Q96DR5  Transport  27011
epith.carc.ass.prot.2prec.
Small proline-rich protein 3  Q9UBC9  Structural/Cytoskeletal  18154
SPARC-like protein 1 precursor  Q14515  Protein Degradation/Inhibitor  75216
Squamous cell carcinoma antigen 1
§ P29508  Protein  Degradation/Inhibitor  44565
Sugar fermentation stimulation protein  Q97VP5  Micro organism  27830
homolog
#
Thioredoxin
§ P10599  Redox  11606
Transaldolase P37837  Energy/metabolism  37540
Transcobalamin I precursor  P20061  Transport  48195
Transgelin-2 P37802  Structural/Cytoskeletal  22260
Transketolase
§ P29401  Energy/metabolism  67878
Triosephosphate isomerase isomerise
§ P60174  Protein  Folding/Repair  26538
Tyrosine recombinase xerC  Q8UC70  Micro organism  34532
Ubiquitin
# O46543  Protein  Degradation/Inhibitor  8583
Von Ebner’s gland protein precursor  P31025  Transport  19250
Zinc-alpha-2-glycoprotein precursor
§ P25311  Energy/metabolism  33872
95% conﬁ  dence proteins    
14-3-3 protein sigma
§ P31947  Signalling 27774
30S ribosomal protein S20
# Q7VQL2  Micro  organism 10264
50S ribosomal protein L5
# Q8CRH2  Micro  organism  20236
Acetyl-CoA acetyltransferase
# P45359  Energy/metabolism  41241
Alanyl-tRNA synthetase
# Q971J4  Micro  organism  103675
Alpha-2-macroglobulin precursor
§ P01023  Protein  Degradation/Inhibitor  163278
Bact.l/permeability-increasing protein-  Q8N4F0  Transport  49172
like 1 prec.
Beta crystallin B1 (Beta-35)
# P53674  Cell  Growth/Differentiation  27892
Carbonyl reductase [NADPH] 1
# P16152  Energy/metabolism  30244
Carcinoembryonic antigen-related cell  P06731  Defense/Immunoresponse  76796
adh. mol.5prec.
§,#
Catalase
§ P04040  Redox  59625
CD9 antigen (p24)
# P21926  Cell  Adhesion/Communication  25285
Chaperone protein htpG  P61185  Micro organism  73731
Cystatin B
# Q862Z5  Protein  Degradation/Inhibitor  11103
Dihydrolipoyllysine-residue P36957  Energy/metabolism  48640
succinyltransferase
#
Ethanolamine utilization protein
# P41793  Micro  organism  49174
F-actin capping protein alpha-2 subunit
# P47755  Structural/Cytoskeletal  32818
Ferredoxin II
# P00237  Micro  organism  9962
Genome polyprotein
# P17594  Micro  organism  255428
Glucose-6-phosphate 1-  P11413  Energy/metabolism  59135
dehydrogenase
#
Heat shock protein HSP 90-beta
# P08238  Protein  Folding/Repair  83133
Hut operon positive regulatory protein
# P10943  Micro  organism  16064
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Table 2. (Continued)
Protein name  Accession nr  Function  Mass (Da)
Hypothetical protein ynaA
# P77658  Micro  organism  37060
Hypothetical UPF0135 protein CPn0137
# Q9Z946 Micro  organism  27236
Ig heavy chain V region UPC10
§,# P01811  Defense/Immunoresponse  13001
Ig kappa chain V-II region TEW
§ P01617  Defense/Immunoresponse  12316
Ig kappa chain V-III region NG9 precursor
§,# P01621  Defense/Immunoresponse  10729
Myeloblastin precursor  P24158  Protein Degradation/Inhibitor  27807
Potential phospholipid-transporting  O60312  Energy/metabolism  167688
ATPase VA
#
Probable Na(+)/H(+) antiporter nhx-9  P35449  Micro organism  75281
Probable serine/threonine-protein kinase
# P28966  Micro  organism  65248
Pyruvate kinase, isozymes R/L
# P30613  Energy/metabolism 61830
Rho GDP-dissociation inhibitor 1  P52565  Signalling  23076
Serum albumin precursor
§ P02768  Transport  69367
Vinculin
# P18206  Cell  adhesion/Communication  123668
Zinc ﬁ  nger protein 446
# Q9NWS9  Signalling  48957
§Proteins that are also found in plasma according to the HUPO Plasma Proteome Initiative list of plasma proteins (www.bioinformatics.
med.umich.edu/app/hupo/ppp/).
#Novel saliva proteins identiﬁ  ed in this study compared to seven previous studies (see Fig. 7).
HUPO list, 84 proteins (38.5%) identiﬁ  ed in the 
current study and indicated in Table 2 are also 
found in plasma. To determine the relevance of the 
identiﬁ  ed proteins, we compared our results to 
seven other proteomics studies (Huang, 2004; 
Wilmarth, 2004; Vitorino, 2004; Hu, 2005; Xie, 
2005; Walz, 2006; Guo, 2006) on whole saliva 
composition. Figure 7 shows that there is only 
partial overlap with our study. Based on this 
analyses 83 new saliva proteins were identiﬁ  ed in 
our study which are indicated in Table 2.
Discussion
There is growing interest in using saliva as a diag-
nostic ﬂ  uid because of its relatively simple and 
non-invasive collection procedures. A prerequisite 
for measuring diagnostic protein markers in saliva 
is that these proteins are stable in saliva. In this 
study we show that relatively rapid protein degra-
dation occurs in whole saliva samples at room 
temperature. We developed a SELDI-based assay 
to quickly monitor sample integrity. With this assay 
we show that protein degradation in saliva at room 
temperature is rapid and starts already during 
sample collection and handling. Three degradation 
products with masses of 2937 Da, 3370 Da and 
4132 Da were discovered that can be used to 
monitor the degradation process and to determine 
the quality of a saliva sample before protein 
analyses. These markers increase 2 to 7-fold over 
a period of 4 hrs storage at room temperature, sug-
gesting they are stable breakdown products of 
larger proteins. The proteome analyses indicates 
that there are at least six proteases present in saliva 
(see Table 2) which are probably involved in the 
observed protein degradation. However, also 13 
KDa
188
62
49
38
28
18
14
6
3
12
Figure 5. SDS-PAGE of saliva proteins. Lane 1 represents the 
molecular weight markers. Lane 2 represents proteins present in 
10 μl of processed saliva. This lane was cut into 30 bands for further 
identiﬁ  cation by LC-MS/MS.36
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protease inhibitor proteins were identiﬁ  ed which 
may counteract protease activity. Nevertheless, the 
overall balance is clearly in favour of degradation. 
Protein breakdown in saliva could be partly inhib-
ited by a protease inhibitor cocktail targeting ser-
ine, cysteine and metallo-proteases. Also in another 
study, that investigated storage of saliva samples 
at different temperatures, only partially prevention 
of degradation was observed with a different 
inhibitor cocktail (Schipper, 2007). More research 
is clearly needed to ﬁ  nd more effective protease 
inhibitor cocktails to prevent degradation. A com-
plicating factor in such studies will be that many 
protease inhibitors are peptides themselves or 
covalently bind to proteins thereby changing their 
masses. Both will interfere with proteomics mea-
surements in biomarker discovery studies but may 
not interfere with ELISA-based measurements of 
individual proteins. Based on the results of our 
study we recommend to freeze samples immedi-
ately after collection, e.g. in liquid nitrogen, to 
minimize protein breakdown. Sample processing 
at 4 °C as well as the use of protease inhibitors can 
help to reduce degradation. Based on a study by 
Schipper et al. (Schipper, 2007) long time storage 
at −80 °C is recommended.
Several different strategies have been employed 
to analyze the saliva proteome such as 2 D gel 
(Huang, 2004; Wilmarth, 2004; Vitorino, 2004; Hu, 
2005; Walz, 2006), capillary iso-electric focusing 
(Guo, 2006), and free ﬂ  ow electrophoresis (Xie, 
2005). Our approach was to fractionate saliva 
proteins by SDS-PAGE followed by LC-MS/MS 
for protein identiﬁ  cation. Overall 218 proteins were 
identiﬁ  ed by this proteomics strategy, not applied 
to saliva before. From the identified proteins 
we deduced the main functions. These are: 
carbohydrate-breakdown, immune response/
defence against bacteria, and protein degradation. 
By comparing our results with seven previous 
proteomics studies (Fig. 7) on whole saliva 
composition we ﬁ  nd only partial overlap with our 
study. 83 new saliva proteins from our study which 
were not previously identiﬁ  ed are indicated in Table 
2. These results show that with each proteomics 
strategy, partial overlapping subsets of saliva 
proteins are identified. Therefore, different 
proteomic approaches will contribute to a more 
comprehensive view of the saliva proteome. Many 
of the identiﬁ  ed proteins are also found in plasma. 
Comparison with the HUPO plasma proteome 
database learned that 38.5% of the identified 
proteins can also be found in plasma. This relatively 
high percentage of plasma proteins in saliva 
illustrate the possibilities for use of saliva as an 
alternative to blood for diagnosis and biomarker 
Cell Adhesion/Communication (3,7%)
Cell Growth/Differetiation (2.3%)
Defense/Immunoresponse (17.9%)
Carbohydrate metabolism (12.8%)
Metabolism/other (6,4%)
Micro organisms (11.0%)
Protein degradation/Inhibition (10.6%) 
Protein Folding/Repair/modification (4,6%)
Signaling (5.5%)
Redox (2.3%)
Structural/Cytoskeletal (14.7%)
Transport (8.3%)
Figure 6. Functional categories of identiﬁ  ed proteins, based on information from Swiss Prot, Source and Human Protein Reference 
Database.
A
A
A
A B
C
D
E
F
G
H
A
A
A
98
38
23
24 14
11
120
180
195
195
154
198 20 83
37
23 3
64
306
271
204
Figure 7. Venn diagrams comparing the proteome results obtained 
with this study (A) versus those achieved by Xie et al. (Xie, 2005) 
(B), Hu et al. (Hu, 2005) (C), Vitorino et al. (Vitorino, 2004) (D), Walz 
et al. (Walz, 2006) (E), Huang et al. (Huang, 2004) (F), Wilmarth 
et al. (Wilmarth, 2004) (G), Guo et al. (Guo, 2006) (H). Only part of 
the data of the study by Guo et al. is publicly available and was used 
in this comparison.37
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discovery. However, protein breakdown in saliva 
samples poses a serious problem for quantitative 
measurements. We conclude that saliva can be a 
promising diagnostic ﬂ  uid when precautions are 
taken towards protein breakdown.
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